Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Genedrive ( (GB:GDR) ) has issued an announcement.
Genedrive PLC announced the initiation of a ‘test of change’ pilot program in NHS Grampian and NHS Western Isles to utilize its CYP2C19 ID Kit for stroke patients in remote and rural areas. The pilot is supported by Scotland’s Centre for Sustainable Delivery and aims to evaluate the impact of rapid genetic testing on treatment outcomes, potentially paving the way for widespread adoption across Scotland. The initiative highlights Genedrive’s leadership in pharmacogenetic testing and its commitment to enhancing healthcare accessibility and precision, especially for underserved regions.
The most recent analyst rating on (GB:GDR) stock is a Hold with a £1.50 price target. To see the full list of analyst forecasts on Genedrive stock, see the GB:GDR Stock Forecast page.
Spark’s Take on GB:GDR Stock
According to Spark, TipRanks’ AI Analyst, GB:GDR is a Neutral.
Genedrive is navigating profitability challenges despite strong revenue growth and a solid balance sheet. Technical analysis indicates bearish momentum, while valuation metrics are unappealing due to lack of profitability. However, recent corporate developments are promising, potentially enhancing market positioning and future prospects.
To see Spark’s full report on GB:GDR stock, click here.
More about Genedrive
Genedrive PLC is a UK-based pharmacogenetic testing company specializing in point-of-care solutions for rapid genetic diagnostics. The company offers low-cost, disposable products like the Genedrive MT-RNR1 ID Kit and the Genedrive CYP2C19 ID Kit, designed to aid clinicians in making precise medical decisions quickly, particularly in emergency and time-critical healthcare environments. Their innovative solutions have been recognized and recommended for use within the UK NHS, with a focus on personalized medicine and improving patient outcomes.
Average Trading Volume: 55,265,109
Technical Sentiment Signal: Strong Sell
Current Market Cap: £9.27M
See more insights into GDR stock on TipRanks’ Stock Analysis page.